{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-156642","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.589809+00:00","generated_at":"2026-06-14T11:25:35.948311+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Catalyst Pharmaceuticals appoints Tamar Thompson to Board; Board expands to 8 members","bullets":["Tamar Thompson appointed to the Board effective May 25, 2023; Board size increased from 7 to 8.","Thompson is VP, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Diseases.","She brings over 20 years of experience in rare diseases, health policy, and government affairs.","Previously served as Executive Director, State Govt Affairs & Federal Policy at Bristol-Myers Squibb.","No family relationships or transactions with Catalyst exceeding $120,000 reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-156642","json":"https://secwatch.observer/filing/0001193125-23-156642.json","markdown":"https://secwatch.observer/filing/0001193125-23-156642.md","text":"https://secwatch.observer/filing/0001193125-23-156642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523156642/0001193125-23-156642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523156642/d511544d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:25:35.948311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bfb989601a","claim":"Tamar Thompson was appointed as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"has appointed Tamar Thompson to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523156642/0001193125-23-156642-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}